HighteawithintrepidUnfortunately for you, you still don’t get it, you’re still stuck in the Telesta mindset of investing with blinders to the information that’s been previously presented and getting caught with your knickers down. (18% trial results vs. 40% the FDA required ring a bell?)
You read but you don’t understand, you see but you don’t process, you hear but you tune-out and ignore, and the simple “two word answer” has been in front of you for months.
Shelf Offerings are a way for companies to raise capital from predatory lenders who want to buy cheap shares in a prospective company.
All other companies before Prometic has had this option available to them, Prometic finally woke up and put this option in their tool bag.
And I’ve posted before (too many times in the past) on how I view Shelf Offerings: they are dilutive in nature, but Prometic’s potential is so large and the Prometic’s market potential share is so vast ($60+ Billion USD) with their two revolutionary drugs (Ryplazim and 4050) that in the long-term scheme of things this type of dilution means nothing to my investment thesis pertaining to Prometic, i.e. in the final analysis you won’t even notice the dilution because the potential market slice is just that big.
HT: pick a new topic to cry “wolf” about.